---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015898"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:19:48.229256+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Q3 net loss $55.7M; second patient dosed in sickle cell trial

## Summary
- Net loss $55.7M ($0.81/share) vs $39.1M ($0.57) in Q3 2021.
- Collaboration revenue fell to $42K from $6.2M a year ago (2021 had BMS opt-in).
- Cash and securities $478.5M, down from $527.6M at June 30; expected to fund into 2024.
- Second patient dosed in Phase 1/2 RUBY trial (EDIT-301 for sickle cell); initial data by year-end.
- Completed editing for first patient in EDITHAL trial (EDIT-301 for TDT); scheduling dosing.

## SEC filing metadata
- accession: 0001558370-22-015898
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/0001558370-22-015898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/edit-20221102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015898
- JSON: https://secwatch.observer/filing/0001558370-22-015898.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015898.txt

## Key facts
- Earnings Releases
  Editas Medicine, Inc. reported the three months ended September 30, 2022 results: revenue $42 thousand, net income $55.7 million, EPS $0.81 per share.
  - Period: the three months ended September 30, 2022
  - Revenue: $42 thousand
  - Net income: $55.7 million
  - EPS: $0.81 per share
  - Result: reported results
  source text: or $0.81 per share, compared to net loss of $39.1 million, or $0.57 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues were $42 thousand for the three months ended September 30, 2022, compared to $6.2 million for the same period in 2021. The 2021 period included revenue recognized for an opt-in by Bristol Myers
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837022015898/0001558370-22-015898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.